Analgesics and Anti-inflammatory Drugs Practice Questions

Q: Which of the following drug classes is not typically considered a first-line treatment for chronic pain management?

Dopamine antagonist. ***Dopamine antagonist*** - **Dopamine antagonists** (e.g., metoclopramide, haloperidol) are primarily used for treating conditions like **psychosis, nausea, and vomiting**, and are **not used for chronic pain management**. - While dopamine pathways can influence pain perception, directly blocking dopamine receptors is not a recognized approach for managing chronic pain and can cause significant adverse effects (extrapyramidal symptoms, sedation). - This is the **correct answer** as they are definitively not first-line (or even considered) for chronic pain. *Opioids* - While **opioids** can be effective for moderate to severe pain, **current guidelines do NOT recommend them as first-line for chronic non-cancer pain** due to risks of addiction, tolerance, and limited long-term efficacy. - However, they may be considered in specific circumstances after other treatments fail, so they are not the best answer here since dopamine antagonists are never used. - First-line options are typically non-opioid analgesics (NSAIDs, acetaminophen) for nociceptive pain. *Antiepileptics* - **Antiepileptics** (e.g., **gabapentin, pregabalin**) are **first-line treatments for neuropathic chronic pain**. - They work by modulating voltage-gated calcium channels and reducing neurotransmitter release, which helps calm overactive nerve signals. - Widely recommended in guidelines for diabetic neuropathy, postherpetic neuralgia, and other neuropathic conditions. *Serotonergic drugs* - **Serotonergic drugs**, particularly **SNRIs** (e.g., **duloxetine, venlafaxine**) and **tricyclic antidepressants** (e.g., amitriptyline), are **first-line agents for several chronic pain conditions**. - Used for fibromyalgia, chronic musculoskeletal pain, and neuropathic pain. - They enhance descending inhibitory pain pathways by increasing serotonin and norepinephrine at the spinal cord level.

Q: Which of the following statements about local anesthetics is FALSE?

Prilocaine is less toxic than lignocaine. ***Prilocaine is less toxic than lignocaine*** - This statement is **false**. While prilocaine has a lower incidence of central nervous system (CNS) toxicity compared to lidocaine, it is associated with a higher risk of **methemoglobinemia**, especially at higher doses, which makes it potentially more toxic in specific scenarios. - Overall, the safety profile of prilocaine, particularly regarding its potential for methemoglobinemia, does not necessarily make it "less toxic" than lignocaine; they have different toxicity profiles. *Lidocaine is shorter acting than bupivacaine* - This statement is **true**. **Lidocaine** is an intermediate-acting local anesthetic, with a duration of action typically ranging from 30 minutes to 3 hours, depending on the dose and presence of a vasoconstrictor. - **Bupivacaine** is a long-acting local anesthetic, with effects lasting 4-8 hours due to its high lipid solubility and protein binding. *Mixture of lignocaine and prilocaine is known as eutectic* - This statement is **true**. A mixture of lidocaine (lignocaine) and prilocaine is known as an **Eutectic Mixture of Local Anesthetics (EMLA)**. - The word "eutectic" refers to the specific proportion of these two substances that results in a lower melting point than either drug individually, allowing them to exist as a liquid at room temperature. This formulation is used for topical anesthesia. *Lignocaine is used as an antiarrhythmic* - This statement is **true**. **Lidocaine (lignocaine)** is a **Class IB antiarrhythmic** drug. - It works by blocking cardiac sodium channels, thereby stabilizing the myocardial cell membrane and decreasing automaticity, making it effective in treating ventricular arrhythmias, especially after myocardial infarction.

Q: What is the primary mechanism of action of colchicine?

Inhibits granulocyte migration. ***Inhibits granulocyte migration*** - Colchicine's primary cellular mechanism involves binding to **tubulin**, preventing its polymerization into **microtubules**. - This microtubule disruption specifically affects **neutrophils/granulocytes**, inhibiting their **chemotaxis, migration, and phagocytic activity**, thereby reducing inflammation. - Among the given options, this represents the **most specific mechanism of action** at the cellular level, making it the best answer. - This is the key mechanism tested in medical examinations when the molecular target (tubulin) is not listed as an option. *Inhibits gouty inflammation* - This describes the **clinical effect** or therapeutic outcome, not the mechanism of action. - While colchicine is highly effective in acute **gout**, this option tells us *what* the drug does clinically, not *how* it works at the cellular/molecular level. *Inhibits the release of chemotactic factors* - Colchicine primarily affects the **cellular response to chemotactic factors** (i.e., preventing neutrophil migration toward inflammatory signals) rather than blocking the release of chemotactic factors themselves. - Its mechanism is on the **responding cell** (neutrophil), not on the source of chemotactic signals. *All of the options* - Incorrect because the other options describe either clinical outcomes or secondary effects. - The **inhibition of granulocyte migration** through microtubule disruption is the fundamental cellular mechanism that explains colchicine's anti-inflammatory effects.

Q: What is the mechanism of action of tacrolimus?

Inhibition of calcineurin. ***Inhibition of calcineurin*** - **Tacrolimus** is a macrolide lactone that functions as a potent **calcineurin inhibitor**. - By inhibiting calcineurin, it prevents the dephosphorylation of **NFAT (Nuclear Factor of Activated T-cells)**, thereby blocking the transcription of genes encoding various pro-inflammatory cytokines, especially **IL-2**, crucial for T-cell proliferation and activation. *Antimetabolite* - **Antimetabolites** interfere with DNA and RNA synthesis, usually by mimicking natural metabolites required for these processes. - Examples include azathioprine or mycophenolate mofetil, which are distinct from the action of tacrolimus. *mTOR inhibitor* - **mTOR inhibitors** (e.g., sirolimus, everolimus) block the mammalian target of rapamycin, a serine/threonine kinase involved in cell growth and proliferation. - While also immunosuppressive, their mechanism is distinct from calcineurin inhibition. *Inhibition of DNA synthesis* - Inhibition of DNA synthesis is a hallmark of **cytotoxic immunosuppressants** or antimetabolites, leading to impaired cell division. - This mechanism is characteristic of drugs like cyclophosphamide or methotrexate, not tacrolimus.

Q: Tocilizumab is an antibody against which interleukin?

IL 6. ***IL 6*** - **Tocilizumab** is a **monoclonal antibody** specifically designed to target the **interleukin-6 (IL-6) receptor**. - By blocking the IL-6 receptor, tocilizumab inhibits the signaling pathways mediated by IL-6, which plays a crucial role in **inflammation** and immune responses in conditions like **rheumatoid arthritis** and **cytokine release syndrome**. *IL 2* - **Interleukin-2 (IL-2)** is important for the proliferation and differentiation of T cells, and antibodies targeting IL-2 or its receptor (e.g., **daclizumab**) are used in different contexts like **transplant rejection prophylaxis** or **autoimmune diseases**. - Tocilizumab does not directly interact with IL-2. *IL 4* - **Interleukin-4 (IL-4)** is a key cytokine involved in **allergic responses** and the differentiation of **Th2 cells**. - Antibodies targeting IL-4 or its receptor (e.g., **dupilumab**) are used in the treatment of conditions like **atopic dermatitis** and asthma. Tocilizumab is not an anti-IL-4 agent. *IL 8* - **Interleukin-8 (IL-8)**, also known as **CXCL8**, is a **chemokine** primarily involved in the recruitment of neutrophils to sites of infection or inflammation. - While IL-8 is an important mediator of inflammation, tocilizumab does not target IL-8; its action is focused on IL-6.

Q: What is the mechanism of action of Daclizumab in immunology?

IL 2 receptor blocker. ***IL 2 receptor blocker*** - Daclizumab is a **monoclonal antibody** that specifically targets the **CD25 subunit** of the **interleukin-2 (IL-2) receptor** on T-lymphocytes. - By blocking this receptor, Daclizumab prevents IL-2 from binding, thereby inhibiting T-cell activation and proliferation, which is useful in preventing **transplant rejection** and treating **multiple sclerosis**. *Activation of cGMP pathway* - The cGMP pathway is commonly associated with the actions of **nitric oxide** and **natriuretic peptides**, affecting smooth muscle relaxation and cellular signaling. - This mechanism is **unrelated** to the immunomodulatory effects of Daclizumab, which primarily acts on T-cell activation. *Inhibition of adenylate cyclase* - **Adenylate cyclase** inhibition typically leads to a decrease in **cyclic AMP (cAMP)** levels, affecting various cellular processes including hormone signaling and neurotransmission. - This mechanism is not the primary mode of action for Daclizumab, which is designed to modulate the immune response via the IL-2 receptor. *Blockade of IL-10 receptor* - **IL-10** is an **anti-inflammatory cytokine** that suppresses immune responses, and blocking its receptor would theoretically enhance inflammation. - Daclizumab's mechanism is centered on inhibiting **pro-inflammatory T-cell activation** by blocking IL-2 signaling, not by interfering with IL-10 pathways.

Q: What is the anti-inflammatory dose of aspirin?

3 - 6 g/d. ***3 - 6 g/d*** - The anti-inflammatory effect of aspirin is typically achieved at higher doses, ranging from **3 to 6 grams per day**, often divided into multiple doses. - This dosage range is necessary to significantly inhibit prostaglandin synthesis, which mediates inflammation and pain. *500 mg/d* - This dose is generally considered to be in the **analgesic and antipyretic range**, effectively reducing pain and fever. - It is often insufficient to achieve a full anti-inflammatory effect, as it does not fully saturate the prostaglandin synthesis pathway. *1 - 2 g/d* - While higher than common analgesic doses, **1-2 g/d of aspirin** may have *some* anti-inflammatory effects but is typically considered a moderate dose. - It might not be sufficient for treating significant inflammatory conditions, falling short of the fully recognized anti-inflammatory dose. *6 - 12 g/d* - Doses within this range are generally considered to be in the **toxic or potentially toxic range** for aspirin. - This high dosage can lead to severe side effects such as **salicylism**, including tinnitus, nausea, vomiting, metabolic acidosis, and even coma, and is not a standard therapeutic anti-inflammatory dose.

Q: A patient comes with a history of asthma and sinusitis. On looking into his medical records, you notice this has been attributed to Samter’s triad. Which drug should be avoided in this patient due to its potential to exacerbate respiratory symptoms?

Aspirin. ***Aspirin (Correct Answer)*** - Samter's triad, or **aspirin-exacerbated respiratory disease (AERD)**, is characterized by **asthma**, **nasal polyps with chronic rhinosinusitis**, and a severe reaction to **aspirin** and other **NSAIDs**. - **Aspirin** inhibits COX-1, leading to an overproduction of **leukotrienes**, which causes bronchoconstriction and exacerbates respiratory symptoms in susceptible individuals. - This is the drug that **must be avoided** in patients with Samter's triad. *Cotrimoxazole (Incorrect)* - **Cotrimoxazole** (trimethoprim-sulfamethoxazole) is an antibiotic not directly involved in the cyclooxygenase pathway. - While allergic reactions can occur, it is **not specifically contraindicated** in Samter's triad. *Co-amoxiclav (Incorrect)* - **Co-amoxiclav** (amoxicillin/clavulanic acid) is a penicillin-class antibiotic, and its mechanism of action does not involve prostaglandin synthesis. - It does not pose a specific risk for exacerbating respiratory symptoms in patients with **Samter's triad**. *Chloramphenicol (Incorrect)* - **Chloramphenicol** is an antibiotic that inhibits bacterial protein synthesis and is not associated with the pathogenesis of Samter's triad. - It does not impact the **cyclooxygenase or lipoxygenase pathways** that are central to AERD.

Q: Pegloticase reduces serum uric acid levels by which mechanism?

Converts uric acid to allantoin. ***Converts uric acid to allantoin*** - Pegloticase is a **recombinant uricase enzyme** that catalyzes the oxidation of uric acid to **allantoin**. - Allantoin is a **water-soluble** substance that is easily excreted by the kidneys, thereby lowering serum uric acid levels. *Inhibits xanthine oxidase* - This is the mechanism of action for drugs like allopurinol and febuxostat, which prevent the formation of uric acid. - Pegloticase works downstream of uric acid formation, by enhancing its degradation. *Inhibits uric acid reabsorption in the kidneys* - This is the mechanism of action for **uricosuric agents** such as probenecid and lesinurad. - These drugs increase the excretion of uric acid by acting on transporters in the renal tubules, but this is not how pegloticase works. *Increases renal excretion of uric acid* - While pegloticase ultimately leads to increased renal excretion of allantoin, its primary mechanism is the **conversion of uric acid to allantoin**, not direct action on renal tubules to excrete uric acid. - Uricosuric agents directly increase renal excretion of uric acid.

Q: A patient diagnosed with Rheumatoid arthritis was on medications. After 2 years, he developed a blurring vision and was found to have corneal opacity. Which drug is most likely to cause this?

Chloroquine. ***Chloroquine*** - **Chloroquine (and hydroxychloroquine)** can accumulate in the **cornea**, leading to **corneal opacity** (vortex keratopathy or cornea verticillata) and **retinopathy**, manifesting as blurring vision. - While corneal changes are usually reversible upon discontinuation, the retinal toxicity, particularly **maculopathy** (bull's eye maculopathy), can be permanent and severe. *Sulfasalazine* - Common side effects include **gastrointestinal upset**, headache, skin rash, and **bone marrow suppression**. - It is not typically associated with **corneal opacity** or significant ocular toxicity. *Leflunomide* - Known for side effects such as **hepatotoxicity**, gastrointestinal issues (diarrhea), **alopecia**, and **hypertension**. - **Ocular side effects** like corneal opacity are not characteristic of leflunomide use. *Methotrexate* - Primary side effects include **bone marrow suppression**, **hepatotoxicity**, **mucositis**, and **pulmonary fibrosis**. - Although it can cause ocular side effects like **conjunctivitis**, it is not a common cause of **corneal opacity**.

Question 1

Which of the following drug classes is not typically considered a first-line treatment for chronic pain management?

Accepted Answer

Dopamine antagonist

Answer

Opioids

Answer

Antiepileptics

Answer

Serotonergic drugs

Question 2

Which of the following statements about local anesthetics is FALSE?

Accepted Answer

Prilocaine is less toxic than lignocaine

Answer

Lidocaine is shorter acting than bupivacaine

Answer

Mixture of lignocaine and prilocaine is known as eutectic

Answer

Lignocaine is used as an antiarrhythmic

Question 3

What is the primary mechanism of action of colchicine?

Accepted Answer

Inhibits granulocyte migration

Answer

Inhibits gouty inflammation

Answer

Inhibits the release of chemotactic factors

Answer

All of the options

Question 4

What is the mechanism of action of tacrolimus?

Accepted Answer

Inhibition of calcineurin

Answer

Antimetabolite

Answer

mTOR inhibitor

Answer

Inhibition of DNA synthesis

Question 5

Tocilizumab is an antibody against which interleukin?

Accepted Answer

IL 6

Answer

IL 8

Answer

IL 2

Answer

IL 4

Question 6

What is the mechanism of action of Daclizumab in immunology?

Accepted Answer

IL 2 receptor blocker

Answer

Activation of cGMP pathway

Answer

Inhibition of adenylate cyclase

Answer

Blockade of IL-10 receptor

Question 7

What is the anti-inflammatory dose of aspirin?

Accepted Answer

3 - 6 g/d

Answer

500 mg/d

Answer

1 - 2 g/d

Answer

6 - 12 g/d

Question 8

A patient comes with a history of asthma and sinusitis. On looking into his medical records, you notice this has been attributed to Samter’s triad. Which drug should be avoided in this patient due to its potential to exacerbate respiratory symptoms?

Accepted Answer

Aspirin

Answer

Cotrimoxazole

Answer

Co-amoxiclav

Answer

Chloramphenicol

Question 9

Pegloticase reduces serum uric acid levels by which mechanism?

Accepted Answer

Converts uric acid to allantoin

Answer

Inhibits xanthine oxidase

Answer

Inhibits uric acid reabsorption in the kidneys

Answer

Increases renal excretion of uric acid

Question 10

A patient diagnosed with Rheumatoid arthritis was on medications. After 2 years, he developed a blurring vision and was found to have corneal opacity. Which drug is most likely to cause this?

Accepted Answer

Chloroquine

Answer

Sulfasalazine

Answer

Leflunomide

Answer

Methotrexate

Analgesics and Anti-inflammatory Drugs — MCQs

Analgesics and Anti-inflammatory Drugs — MCQs

On this page

Practice by Chapter

Want unlimited practice?